Literature DB >> 16596252

E2F-1 is a critical modulator of cellular senescence in human cancer.

Chaehwa Park1, Inkyoung Lee, Won Ki Kang.   

Abstract

Senescence limits cellular proliferation, and therefore might be a mechanism which could suppress the progression of cancer. Herein we show that E2F1, a transcription factor essential to a cell cycle progress and a main target of tumor suppressor Rb, is a critical barrier for the induction of senescence. Human cancer cells transfected with siE2F1 were shown to express replicative senescence markers, in addition to yielding positive results upon SA-beta-Gal staining. Consistent with the notion of the critical role in senescence of E2F1, cells which overexpressed E2F1 proved to be immune to the induction of senescence. Importantly, it appears that E2F1 depletion-induced cancer cell senescence is not reliant on the integrity of either Rb or p53. Our results provide a molecular explanation for the selectivity with which senescence induction occurs, and also provides insights into the possibility of using E2F1 as a therapeutic target in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596252

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  31 in total

1.  Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.

Authors:  Jason P Carey; Ashley Evans Knowell; Swathi Chinaranagari; Jaideep Chaudhary
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

2.  Differential expression of oncogenic miRNAs in proliferating and senescent human fibroblasts.

Authors:  Miao Wang; Zhaojie Cheng; Tian Tian; Jingwen Chen; Fei Dou; Mingzhou Guo; Yu-Sheng Cong
Journal:  Mol Cell Biochem       Date:  2011-03-17       Impact factor: 3.396

3.  Targeting LINC00673 expression triggers cellular senescence in lung cancer.

Authors:  Anna Roth; Karine Boulay; Matthias Groß; Maria Polycarpou-Schwarz; Frédérick A Mallette; Marine Regnier; Or Bida; Doron Ginsberg; Arne Warth; Philipp A Schnabel; Thomas Muley; Michael Meister; Heike Zabeck; Hans Hoffmann; Sven Diederichs
Journal:  RNA Biol       Date:  2018-12-07       Impact factor: 4.652

4.  Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.

Authors:  Erika S Dahl; Raquel Buj; Kelly E Leon; Jordan M Newell; Yuka Imamura; Benjamin G Bitler; Nathaniel W Snyder; Katherine M Aird
Journal:  Mol Cancer Res       Date:  2019-05-20       Impact factor: 5.852

Review 5.  Caveolin-1, a master regulator of cellular senescence.

Authors:  Daniela Volonte; Ferruccio Galbiati
Journal:  Cancer Metastasis Rev       Date:  2020-06       Impact factor: 9.264

6.  Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.

Authors:  Anne Cooley; Stanislav Zelivianski; Jacqueline S Jeruss
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

7.  Functional variants at the miRNA binding sites of the E2F1 gene and its mRNA expression.

Authors:  Yunzhao Zhao; Lin Tang; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Oncol Lett       Date:  2012-10-26       Impact factor: 2.967

8.  DPY30 regulates pathways in cellular senescence through ID protein expression.

Authors:  Elisabeth Simboeck; Arantxa Gutierrez; Luca Cozzuto; Malte Beringer; Livia Caizzi; William M Keyes; Luciano Di Croce
Journal:  EMBO J       Date:  2013-07-19       Impact factor: 11.598

Review 9.  Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.

Authors:  Mark W Gramling; Frank C Church
Journal:  Thromb Res       Date:  2010-01-15       Impact factor: 3.944

Review 10.  Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression.

Authors:  Kaumudi Bhawe; Deodutta Roy
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.